Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MDS-001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia